Compounds > azd3514
Page last updated: 2024-08-03 16:47:31

azd3514

Description

AZD3514: in Phase I clinical trial in patients with castrate-resistant prostate cancer (2/2013); structure in first source [MeSH]

Cross-References

ID SourceID
PubMed CID46893585
CHEMBL ID2346976
SCHEMBL ID3056463
MeSH IDM0588024

Synonyms (35)

Synonym
bdbm50432188
S7040
azd-3514
azd 3514
CHEMBL2346976 ,
azd3514
cs-1443 ,
HY-16079
1240299-33-5
SCHEMBL3056463
6-(4-{4-[2-(4-acetylpiperazin-1-yl)ethoxy]phenyl}piperidin-1-yl)-3-(trifluoromethyl)-7,8-dihydro[1,2,4]triazolo[4,3-b]pyridazine
1-(4-(2-(4-(1-(3-(trifluoromethyl)-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)piperazin-1-yl)ethanone
unii-127dss8x7j
1-{4-[2-(4-{1-[3-(trifluoromethyl)-7,8-dihydro[1,2,4]triazolo[4,3-b]pyridazin-6-yl]piperidin-4-yl}phenoxy)ethyl]piperazin-1-yl}ethan-1-one
DTXSID80677133
AKOS027422738
HMS3652H18
NCGC00386284-05
ethanone, 1-(4-(2-(4-(1-(7,8-dihydro-3-(trifluoromethyl)-1,2,4-triazolo(4,3-b)pyridazin-6-yl)-4-piperidinyl)phenoxy)ethyl)-1-piperazinyl)-
azd 3514 [who-dd]
127DSS8X7J ,
SW219684-1
BCP07896
FT-0735650
SB19559
1-[4-[2-[4-[1-[3-(trifluoromethyl)-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]piperidin-4-yl]phenoxy]ethyl]piperazin-1-yl]ethanone
CCG-264708
EX-A1806
F84948
MS-29635
AC-35907
nsc-765776
nsc765776
NCGC00386284-02
Z2037280630

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency13.1373AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency3.0112AID1645841
GVesicular stomatitis virusPotency11.9877AID1645842
Interferon betaHomo sapiens (human)Potency12.8499AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency11.9877AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency11.9877AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency11.9877AID1645842

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Androgen receptorHomo sapiens (human)IC501.7789AID1673919; AID1885087; AID738102
Androgen receptorHomo sapiens (human)Ki3.1333AID1673917; AID1673918; AID738094
Androgen receptorRattus norvegicus (Norway rat)Ki5.0000AID738099
Cannabinoid receptor 1Mus musculus (house mouse)IC501.7783AID738102
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50100.0000AID738101

Bioassays (28)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937		High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1885087Antagonist activity at Androgen receptor (unknown origin) assessed as downregulation of AR2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
ISSN: 1520-4804		Therapeutic Strategies to Target the Androgen Receptor.
AID738097Fraction unbound in human plasma by equilibrium dialysis method2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID738100Lipophilicity, log D of the compound at pH 7.42013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID1673919Induction of androgen receptor degradation in human LNCaP cells2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
ISSN: 1520-4804		Monomeric Targeted Protein Degraders.
AID738086Clearance in Han Wistar rat at 4 umol/kg, iv and 5 umol/kg, po2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID1673918Inhibition of full length androgen receptor (unknown origin)2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
ISSN: 1520-4804		Monomeric Targeted Protein Degraders.
AID738101Inhibition of human ERG by IonWorks assay2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID738082Oral bioavailability in Han Wistar rat at 5 umol/kg2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID738102Inhibition of androgen receptor-mediated cellular downregulation in human LNCAP cells assessed as decrease in nuclear receptor level after 20 to 22 hrs by laser-scanning fluorescence microplate cytometeric analysis2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID738095Thermodynamic solubility of the compound in phosphate buffer after 24 hrs2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID1885089Oral bioavailability in dog2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
ISSN: 1520-4804		Therapeutic Strategies to Target the Androgen Receptor.
AID738096Fraction unbound in Han Wistar rat plasma by equilibrium dialysis method2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID738090Volume of distribution at steady state in Han Wistar rat at 4 umol/kg, iv and 5 umol/kg, po2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID738098Intrinsic clearance in human hepatocytes measured per 10'6 cells2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID738092Volume of distribution at steady state in beagle dog at 2 umol/kg, iv and 10 umol/kg, po2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID738099Binding affinity to rat androgen receptor ligand binding domain by fluorescence polarization assay2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID738083Oral bioavailability in beagle dog at 10 umol/kg2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID738094Displacement of [3H]R1881 from full length androgen receptor in human LNCAP cells2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID738081Antiandrogenic activity in immature castrated Hershberger rat model assessed as inhibition of testosterone propionate-induced seminal vesicle growth at 50 to 100 mg/kg, po bid for 7 days2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID738088Clearance in beagle dog at 2 umol/kg, iv and 10 umol/kg, po2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405		Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
AID1885048Oral bioavailability in rat2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
ISSN: 1520-4804		Therapeutic Strategies to Target the Androgen Receptor.
AID1673917Inhibition of androgen receptor LBD domain (unknown origin)2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
ISSN: 1520-4804		Monomeric Targeted Protein Degraders.

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (64.29)24.3611
2020's5 (35.71)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (14.29%)5.53%
Reviews2 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (71.43%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
bicalutamide
2
(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol		201320226.5low000011
oxandrolone
1
17beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid		anabolic agent;
androgen		202220222.0low000001
medroxyprogesterone acetate
1
20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive		202220222.0low000001
dihydrotestosterone
1
17beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite		202220222.0low000001
nitrogenase stabilizing-protective protein, bacteria
1
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamideandrogen antagonist;
antineoplastic agent		202220222.0low000001
hydroxyflutamide
1
202220222.0low000001
metribolone
1
17beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid		androgen202220222.0low000001
(S)-bicalutamide
1
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide202220222.0medium000001
artenimol
1
202020204.0low000010
epi 001
1
diether;
organochlorine compound		androgen antagonist202220222.0medium000001
pyrvinium
1
quinolinium ionanthelminthic drug;
antineoplastic agent		202220222.0low000001
andarine
1
acetamides;
anilide		202220222.0low000001
lg 121071
1
202220222.0medium000001
bms-564929
1
202220222.0medium000001
mk 2866
1
202220222.0low000001
lgd 2226
1
202220222.0medium000001
mdv 3100
1
(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent		202220222.0low000001
mln 8237
1
benzazepine202020204.0low000010
apalutamide
1
202220222.0low000001
pf 998425
1
202220222.0high000001
lrrk2-in1
1
aromatic amine;
aromatic ether;
N-acylpiperidine;
N-alkylpiperazine;
pyrimidobenzodiazepine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor		202020204.0low000010
pf 956980
1
N-acylpiperidine;
N-acylpyrrolidine;
pyrrolopyrimidine;
tertiary amino compound		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor202020204.0medium000010
gne-7915
1
202020204.0medium000010
gne-0877
1
202020204.0medium000010
9-(1-methyl-4-pyrazolyl)-1-[1-(1-oxoprop-2-enyl)-2,3-dihydroindol-6-yl]-2-benzo[h][1,6]naphthyridinone
1
naphthyridine derivative202020204.0medium000010
MLI-2
1
aromatic ether;
cyclopropanes;
indazoles;
morpholines;
pyrimidines;
tertiary amino compound		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor202020204.0medium000010
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
abiraterone acetate
1
pyridines;
sterol ester		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor;
prodrug		2013201311.0low000010
mdv 3100
1
(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent		2013201311.0low000010
olaparib
1
cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines		antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor		201820186.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Androgen-Independent Prostatic Cancer0
5
201320227.6medium100041
Breast Cancer0
1
201820186.0low000010
Breast Neoplasms0
1
201820186.0low000010
Cancer of Prostate0
2
2013201410.5low000020
Cells, Neoplasm Circulating0
2
201420159.5low100020
Congenital Zika Syndrome0
1
202020204.0low000010
Disease Models, Animal0
2
201320207.5low000020
Emesis0
1
201620168.0low100010
Nausea0
1
201620168.0low100010
Prostatic Neoplasms0
2
2013201410.5low000020
Prostatic Neoplasms, Castration-Resistant1
5
201320227.6medium100041
Sensitivity and Specificity0
1
2014201410.0low000010
Vomiting0
1
201620168.0low100010
Zika Virus Infection0
1
202020204.0low000010

Bioavailability (2)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019
AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.
Molecular cancer therapeutics, , Volume: 12, Issue:9		2013

Dosage (1)

ArticleYear
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies.
Investigational new drugs, , Volume: 33, Issue:3		2015